To date, α-PD-1/PD-L1 therapy has shown potent antitumor activity in various cancers, such as melanoma, non-small cell lung cancer (NSCLC), gastric cancer, liver cancer, urothelial cancer, lymphoma, and all microsatellite instability (MSI)-high cancers. The gene discussed is CD274; the disease is non-small cell lung carcinoma.